Skip to main content
TIANYU BIO-TECHNOLOGY CO.,LTD. logo

TIANYU BIO-TECHNOLOGY CO.,LTD. — Investor Relations & Filings

Ticker · 603717 ISIN · CNE1000030W1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,618 across all filing types
Latest filing 2026-05-20 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 603717

About TIANYU BIO-TECHNOLOGY CO.,LTD.

https://www.tianyubiotech.com/

TIANYU BIO-TECHNOLOGY CO.,LTD. specializes in the research, development, and large-scale production of active pharmaceutical ingredients (APIs) and advanced pharmaceutical intermediates. The company focuses on therapeutic areas such as cardiovascular health, diabetes management, and anti-viral treatments. Its core product portfolio includes various sartan-based intermediates and other complex organic synthesis products. TIANYU BIO-TECHNOLOGY emphasizes rigorous quality management systems and adheres to international regulatory standards to ensure product safety and efficacy. By leveraging advanced chemical synthesis technologies and a robust R&D infrastructure, the company provides customized manufacturing solutions and high-quality chemical components to global pharmaceutical partners. Its operations are characterized by a commitment to technical innovation and process optimization in the synthesis of complex molecules.

Recent filings

Filing Released Lang Actions
上海市锦天城律师事务所关于天域生物科技股份有限公司2025年年度股东会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 75% confidence The document is a legal opinion letter (法律意见书) issued by the company’s law firm concerning the legality and procedure of the 2025 Annual General Meeting, and it includes detailed vote counts and outcomes for each resolution passed at that meeting. Thus it functions as an official presentation of AGM voting results, fitting the “Declaration of Voting Results & Voting Rights Announcements” category.
2026-05-20 Chinese
关于董事辞任的公告
Board/Management Information Classification · 92% confidence The document is an announcement by the company regarding the resignation of a board director (‘董事辞任的公告’, details of the director’s departure, effective date, and impact on the board). This falls squarely under Board/Management Information (MANG).
2026-05-20 Chinese
关于公司2025年度对外担保预计的进展公告
Regulatory Filings Classification · 23% confidence The document is a formal corporate announcement detailing the company’s external guarantee arrangements and progress for the 2025 fiscal year. It does not contain full financial statements or serve as an investor presentation, earnings release, or management report. Nor is it announcing a report publication or any specific regulatory form. As a miscellaneous regulatory disclosure about contingent guarantee obligations, it falls under the general “Regulatory Filings” category (RNS).
2026-05-12 Chinese
上海市锦天城律师事务所关于天域生物科技股份有限公司2026年第二次临时股东会的法律意见书
Regulatory Filings
2026-02-27 Chinese
关于联席总裁辞任暨选举董事长、调整董事会专门委员会成员的公告
Regulatory Filings
2026-02-27 Chinese
2026年第二次临时股东会决议公告
Regulatory Filings
2026-02-27 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.